Stocks
Exelixis, Inc.EXEL
NASDAQHealthcareBiotechnology$41.24+0.17%
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing therapies for cancer treatment, it has gained investor attention for its flagship product, Cabometyx, which targets advanced renal cell carcinoma and hepatocellular carcinoma. The company’s pipeline and strategic collaborations position it as a key player in oncology innovation.
Market Cap: $11.1B52W Range: $32.38 – $49.62
Congressional Interest in Exelixis, Inc. (EXEL)
9 members of Congress have disclosed 13 trades in Exelixis, Inc. (EXEL), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 7 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
13
Unique Politicians
9
Buys
6
Sells
7
Who in Congress Is Trading EXEL?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-08-04 | Joseph P. Kennedy | sell | $15K – $50K |
| 2020-06-05 | Kurt Schrader | sell | $15K – $50K |
| 2019-06-04 | Donna Shalala | sell | $1K – $15K |
| 2019-04-16 | Donna Shalala | sell | $1K – $15K |
| 2019-02-06 | Donna Shalala | buy | $1K – $15K |
| 2019-01-09 | Donna Shalala | buy | $1K – $15K |
| 2018-12-27 | KENNY MARCHANT | sell | $50K – $100K |
| 2018-04-09 | MIKE KELLY | buy | $1K – $15K |
| 2017-12-18 | MICHAEL T. MCCAUL | sell | $15K – $50K |
| 2017-07-27 | JOHN K. DELANEY | buy | $15K – $50K |
| 2017-07-24 | JOHN K. DELANEY | buy | $15K – $50K |
| 2016-03-10 | David P. Roe | sell | $1K – $15K |
| 2007-11-12 | THOMAS J. ROONEY | buy | $15K – $50K |